chartexchange

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

GlobeNewswire Inc. | Oct 14, 2026 8:00 AM EDT

BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing  in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that John W. Frederick has been appointed to its board of directors. Mr. Frederick brings extensive executive leadership experience spanning financial strategy, capital markets, corporate governance and operational transformation across public and private companies.

Read original article